Promoting Immunotherapy Efficacy With Low-Dose Liver RT

The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.

Trial Details

NCT ID
NCT07225036
Phase
NA
Sponsor
Jordan Kharofa
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • LD-LRT
Locations (sample)
  • Cincinnati, Ohio, United States|39.12711,-84.51439

Key Eligibility Criteria

  • Age ≥18 years.
  • ECOG performance status ≤2 (or Karnofsky ≥60%, see Appendix A).
  • Patients must have adequate organ and marrow function to receive standard of care immunotherapy and/or chemoimmunotherapy as per the treating medic…
  • Must be planning to, and able to, undergo active treatment with PD-L1 or PD-1 checkpoint immunotherapy given per standard care throughout the durat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →